2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Thursday, March 19, 2026

6:00PM-7:00PM: Abstract Number: 058

Increasing Reproductive Health Counseling and Screening in a Pediatric Rheumatology Clinic Using Quality Improvement Principles and Diverse Group of Stakeholders

Posters: Quality, Health Services, and Education Research I

6:00PM-7:00PM: Abstract Number: 073

Interleukin-6 and Interleukin-12 Stimulation Increases Fibroblast Migration in Localized Scleroderma and Healthy Control Primary Fibroblasts

Posters: Genetics and Pathogenesis I

6:00PM-7:00PM: Abstract Number: 056

Journey Maps of the Diagnostic Process: Insights from Caregivers of Patients with Juvenile Idiopathic Arthritis

Posters: Quality, Health Services, and Education Research I

6:00PM-7:00PM: Abstract Number: 013

Kikuchi-Fujimoto’s Disease in Systemic Lupus Erythematosus: Single-center Experience

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 025

Longitudinal Single Cell Transcriptomic Analysis of Type I and II Interferon (IFN) Response Genes (IRG) in Refractory Juvenile Dermatomyositis (JDM) Patients with Baricitinib Treatment

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 011

Lung Transplant for Pediatric Dermatomyositis Patients with Interstitial Lung Disease: A Single-Center Experience

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 005

Magnetic Resonance Enterography Detected Sacroiliitis in Pediatric Crohn’s Disease: A Retrospective Cohort Study

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 022

Mental Health concerns in Patients with Juvenile Idiopathic Arthritis and Their Caregivers: A Systematic Review

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 032

Methotrexate Response in Systemic JIA: Real-World Evidence from a Tertiary-Care Cohort

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 049

Novel Insights of Brain MRI Features in Neonatal Lupus Erythematosus with Hydrocephalus

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 015

Obinutuzumab Induces Histologic Remission And Deep Kidney Parenchymal B-Cell Depletion In Patients With Lupus Nephritis: Exploratory Analyses From The REGENCY Trial

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 037

Off-the-Shelf Anti-CD19 CAR T-cell Therapy with Reduced or No Conditioning Chemotherapy Demonstrates Efficacy and Tolerability in Systemic Lupus Erythematosus: Meaningful Activity Supports Planned Adolescent Enrollment

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 029

Oral vs Subcutaneous Methotrexate at High Dose for Pediatric Anterior Uveitis

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 041

Pediatric Behçet’s Disease: A 13-Year Single-Center Experience Highlighting Diagnostic Delays and High Neurological Burden

Posters: Clinical and Therapeutic Aspects I

6:00PM-7:00PM: Abstract Number: 057

Pediatric Learners’ Knowledge Retention and Diagnostic Confidence after High-Fidelity Pediatric Rheumatology Simulation

Posters: Quality, Health Services, and Education Research I

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].